Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Heald

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Journal of Medicinal Chemistry|December 4, 2024
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid CancersChristopher L Carroll, Michael G Johnson, Yanbing Ding, et al.
Journal of Medicinal Chemistry|February 23, 2023
Correction to "Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta"Martin L Stockley, Giovanni Benedetti, Peter Blencowe, et al.
Journal of Medicinal Chemistry|September 17, 2025
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 InhibitorSam E Mann, Julien Lefranc, Omar Alkhatib, et al.
Nature Communications|June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Journal of Medicinal Chemistry|December 4, 2024
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid CancersChristopher L Carroll, Michael G Johnson, Yanbing Ding, et al.
Journal of Medicinal Chemistry|February 23, 2023
Correction to "Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta"Martin L Stockley, Giovanni Benedetti, Peter Blencowe, et al.
Journal of Medicinal Chemistry|September 17, 2025
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 InhibitorSam E Mann, Julien Lefranc, Omar Alkhatib, et al.
Nature Communications|June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Pageof 11